Phase II study of biweekly cetuximab and irinotecan for unresectable advanced/recurrent colorectal cancer. Phoenix study
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2618942
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Cetuximab 500 mg/m2/biweekly CPT-11 150 mg/m2/biweekly
Primary outcome(s): response rate
Study Design: Single arm Non-randomized
创建时间：
2009-12-15
